C4 Therapeutics, Inc. (CCCC)
Largest Insider Buys in Sector
CCCC Stock Price History Chart
CCCC Stock Performance
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC …
Insider Activity of C4 Therapeutics, Inc.
Over the last 12 months, insiders at C4 Therapeutics, Inc. have bought $0 and sold $0 worth of C4 Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at C4 Therapeutics, Inc. have bought $185,613 and sold $15.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,667 shares for transaction amount of $31,735 was made by Koppikar Utpal (director) on 2023‑02‑08.
List of Insider Buy and Sell Transactions, C4 Therapeutics, Inc.
| 2023-02-08 | director | 5,667 0.0109% | $5.60 | $31,735 | -44.36% | |||
| 2022-04-12 | President & CEO | 10,000 0.0196% | $8.40 | $84,000 | -7.59% | |||
| 2022-01-04 | Sale | Chief Medical Officer | 30,000 0.0617% | $31.66 | $949,935 | -69.95% | ||
| 2021-12-17 | Sale | director | 1,510 0.0032% | $30.25 | $45,678 | -69.12% | ||
| 2021-11-19 | Sale | director | 1,510 0.0034% | $40.11 | $60,566 | -73.29% | ||
| 2021-10-15 | Sale | director | 1,510 0.0034% | $44.94 | $67,859 | -72.36% | ||
| 2021-10-01 | Sale | Chief Medical Officer | 30,000 0.0644% | $45.43 | $1.36M | -54.31% | ||
| 2021-09-27 | Sale | director | 3,700 0.0076% | $50.04 | $185,146 | -56.99% | ||
| 2021-09-24 | Sale | director | 6,030 0.0127% | $50.10 | $302,130 | -56.18% | ||
| 2021-09-23 | Sale | director | 38,360 0.079% | $50.41 | $1.93M | -56.89% | ||
| 2021-09-22 | Sale | director | 21,096 0.0435% | $50.10 | $1.06M | -55.96% | ||
| 2021-09-21 | Sale | director | 20,642 0.0426% | $50.14 | $1.03M | -55.74% | ||
| 2021-09-17 | Sale | director | 21,680 0.0448% | $50.05 | $1.08M | -55.30% | ||
| 2021-09-17 | Sale | director | 1,510 0.0031% | $49.89 | $75,334 | -55.30% | ||
| 2021-09-16 | Sale | director | 52,998 0.1074% | $48.65 | $2.58M | -54.79% | ||
| 2021-09-15 | Sale | director | 108,386 0.2237% | $48.82 | $5.29M | -53.81% | ||
| 2021-09-14 | Sale | director | 1,968 0.0041% | $50.02 | $98,434 | -54.13% | ||
| 2021-09-13 | Sale | director | 13,320 0.0276% | $50.07 | $666,948 | -54.30% | ||
| 2021-09-10 | Sale | director | 5,100 0.0107% | $50.00 | $255,022 | -53.58% | ||
| 2021-09-10 | Sale | Chief Legal Officer | 25,000 0.0289% | $27.49 | $687,250 | -53.58% |
Insider Historical Profitability
| Salter Malcolm | director | 10952 0.0155% | $3.87 | 1 | 8 | +39.65% |
| Hirsch Andrew | President & CEO | 10000 0.0142% | $3.87 | 1 | 0 | <0.0001% |
| Koppikar Utpal | director | 5667 0.008% | $3.87 | 1 | 0 | <0.0001% |
| MCKEE WILLIAM | Chief Financial Officer | 5263 0.0075% | $3.87 | 1 | 0 | +39.65% |
| COHEN MARC A | 5030 0.0071% | $3.87 | 1 | 0 | +39.65% |
Institutional Investor Ownership
| State Street | $58.44M | 10.4 | 7.15M | +4,503.94% | +$57.17M | <0.01 | |
| RA Capital Management, L.P. | $39.85M | 7.09 | 4.88M | 0% | +$0 | 0.04 | |
| Wasatch Advisors | $35.36M | 6.29 | 4.33M | -39.37% | -$22.96M | 0.19 | |
| Lynx1 Capital Management Lp | $29.7M | 5.28 | 3.63M | +15.96% | +$4.09M | 1.57 | |
| Commodore Capital, LP | $27.86M | 4.96 | 3.41M | -10.25% | -$3.18M | 0.11 |